NIPRO CORPORATION, through its U.S.-based subsidiary Nipro Medical Corporation, has announced the commercial launch of ELISIO-HX, a medium-cutoff dialyzer featuring super high-flux membrane technology, following its recent U.S. Food and Drug Administration (FDA) 510(k) clearance. The launch marks a significant advancement in kidney care by making expanded hemodialysis more accessible to dialysis providers across the United States.

The ELISIO-HX dialyzer has been developed to improve the removal of larger middle molecules, substances associated with inflammation and other complications that are not efficiently eliminated through conventional high-flux dialysis. While therapies targeting enhanced middle molecule clearance have long been available, broader adoption has been constrained by supply limitations, high costs, operational complexity and infrastructure requirements.

With ELISIO-HX, Nipro aims to overcome these barriers by offering a scalable solution that integrates with existing hemodialysis systems. The dialyzer incorporates a precisely engineered super high-flux membrane with a controlled pore structure designed to extend the removal of larger middle molecules while preserving albumin, a key protein essential for maintaining patients' nutritional status.

A key advantage of the technology is its compatibility with existing dialysis infrastructure, allowing healthcare providers to introduce expanded hemodialysis into routine clinical practice without investing in new equipment, altering treatment workflows or retraining staff.

James McGetrick, President of North America, Nipro Medical Corporation, said, "Providers have sought a scalable way to improve middle-molecule clearance, but supply constraints, operational complexity and infrastructure requirements have impacted adoption rates in the U.S. The ELISIO-HX is designed to help overcome those barriers, making this approach accessible through existing dialysis delivery models and at a scale that has not previously been possible."

According to the company, ELISIO-HX is also designed to support a broader patient population. Unlike certain advanced dialysis therapies that require higher blood flow rates or specialised treatment conditions, the new dialyzer may be suitable for patients with vascular access limitations and others who may not be ideal candidates for high-volume therapies. This flexibility is expected to support wider adoption across diverse dialysis settings.

Nipro noted that the dialyzer enables providers to implement expanded hemodialysis within existing treatment schedules, staffing models and equipment environments, helping maintain operational efficiency while enhancing treatment options.

Dr. Jeff Giullian, Chief Medical Officer, DaVita, said, "Every advancement in dialysis should be measured by its potential to improve the patient experience. The availability of ELISIO-HX expands the range of treatment options available to nephrologists and the patients they care for, bringing an important innovation into routine practice. More choice enables more individualised care and that's ultimately what patients deserve."